JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB185901

Chromatin Accessibility Assay Kit

Be the first to review this product! Submit a review

|

(13 Publications)

Chromatin Accessibility Assay Kit ab185901 is a complete set of optimized reagents designed for conducting a gene-specific analysis of chromatin accessibility including nucleosome/transcription factor positioning from various biological samples via real time PCR.
2 Images
RT-PCR - Chromatin Accessibility Assay Kit (AB185901)
  • RT-PCR

Supplier Data

RT-PCR - Chromatin Accessibility Assay Kit (AB185901)

Chromatin accessibility of closed chromatin (heterochromatin).

Amplification of proximal promoter regions for the constitutively repressed target gene was carried out in MDA-231 cells by using negative control primers. Red and green lines : Nse-untreated; Blue and pink lines : Nse-treated. The difference of Ct values between Nse-treated and untreated is <1.5 cycles.

RT-PCR - Chromatin Accessibility Assay Kit (AB185901)
  • RT-PCR

Supplier Data

RT-PCR - Chromatin Accessibility Assay Kit (AB185901)

Chromatin accessibility of opened chromatin (euchromatin).

Amplification of proximal promoter regions for the constitutively expressed target gene was carried out in MDA-231 cells by using positive control primers. Red and green lines : Nse-untreated; Blue lines : Nse-treated. The difference of Ct values between Nse-treated and untreated is > 7 cycles.

Key facts

Sample types

Tissue, Suspension cells, Adherent cells

Results type

Quantitative

Assay time

1h 30m

Product details

Chromatin Accessibility Assay Kit ab185901 is a complete set of optimized reagents designed for conducting a gene-specific analysis of chromatin accessibility including nucleosome/transcription factor positioning from various biological samples via real time PCR.

The chromatin accessibility assay works on the principle that accessible chromatin is easily accessed by a nuclease mix to digest the DNA. When the DNA from the nuclease-treated sample and a no-nuclease control is analyzed for a particular gene by PCR, the more accessible the chromatin at that gene, the lower the signal of the nuclease-treated sample relative to the no-nuclease control.

Chromatin accessibility assay protocol summary:
- lyze cells and extract chromatin by adding lysis buffer to cell pellet, resuspending and incubating for 10 min
- centrifuge at 5,000 rpm for 5 min, discard supernatant, resuspend chromatin pellet in wash buffer and centrifuge again
- resuspend chromatin pellet in nuclease reaction mix (or no-nuclease control mix to controls) and incubate for 4 min
- add stop solution and incubate for 10 min
- add Proteinase K and incubate for 60 min
- add samples to DNA binding columns, spin, and discard flow through
- add DNA washing solution to columns, spin, and discard flow through 3 times
- add elution solution and spin to elute DNA
- analyze gene target with PCR and compare nuclease-treated to no-nuclease control

Other Notes
The accessibility of regulatory elements in chromatin is critical for many aspects of gene regulation. Nucleosomes positioned over regulatory elements inhibit access of transcription factors to DNA. To elucidate the role of the interactions between chromatin and transcription factors, it is crucial to determine chromatin accessibility through mapping of the nucleosome positioning along the genome. In general, the more condensed the chromatin, the more difficult it is for transcription factors and other DNA binding proteins to access DNA and carry out their tasks. The more accessible the DNA, the more likely surrounding genes are actively transcribed. The presence (or the absence) of nucleosomes directly or indirectly affects a variety of other cellular and metabolic processes such as recombination, replication, centromere formation, and DNA repair.

What's included?

{ "values": { "48Test": { "sellingSize": "48 Test", "publicAssetCode":"ab185901-48Test", "assetComponentDetails": [ { "size":"1 x 50 Unit", "name":"F-Spin Column", "number":"AB185901-CMP16", "productcode":"" }, { "size":"1 x 50 Unit", "name":"F-Collection Tube", "number":"AB185901-CMP15", "productcode":"" }, { "size":"1 x 10 µL", "name":"Negative Control Primer-F (20 μM)", "number":"AB185901-CMP05", "productcode":"" }, { "size":"1 x 10 mL", "name":"10X Wash Buffer", "number":"AB185901-CMP04", "productcode":"" }, { "size":"1 x 15 mL", "name":"DNA Binding Solution", "number":"AB185901-CMP01", "productcode":"" }, { "size":"1 x 3 mL", "name":"10X DNA Washing Solution", "number":"AB185901-CMP02", "productcode":"" }, { "size":"1 x 10 µL", "name":"Positive Control Primer-F (20 μM)", "number":"AB185901-CMP09", "productcode":"" }, { "size":"1 x 11 mL", "name":"10X Lysis Buffer", "number":"AB185901-CMP03", "productcode":"" }, { "size":"1 x 50 µL", "name":"Nuclease Mix", "number":"AB185901-CMP08", "productcode":"" }, { "size":"1 x 1 mL", "name":"Elution Solution", "number":"AB185901-CMP14", "productcode":"" }, { "size":"1 x 0.5 mL", "name":"Reaction Stop Solution", "number":"AB185901-CMP13", "productcode":"" }, { "size":"1 x 10 µL", "name":"Positive Control Primer-R (20 μM)", "number":"AB185901-CMP10", "productcode":"" }, { "size":"1 x 10 µL", "name":"Negative Control Primer-R (20 μM)", "number":"AB185901-CMP06", "productcode":"" }, { "size":"1 x 3 mL", "name":"Nuclear Digestion Buffer", "number":"AB185901-CMP07", "productcode":"" }, { "size":"1 x 50 µL", "name":"1000X Protease Inhibitor Cocktail", "number":"AB185901-CMP11", "productcode":"" }, { "size":"1 x 110 µL", "name":"Proteinase K (10 mg/mL)", "number":"AB185901-CMP12", "productcode":"" } ] } } }

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
Multi
Appropriate long-term storage conditions
Multi
Storage information
Please refer to protocols

Product protocols

Target data

Publications (13)

Recent publications for all applications. Explore the full list and refine your search

Nature communications 16:5393 PubMed40562767

2025

PADI4-mediated citrullination of histone H3 stimulates HIV-1 transcription.

Applications

Unspecified application

Species

Unspecified reactive species

Luca Love,Bianca B Jütte,Birgitta Lindqvist,Hannah Rohdjess,Oscar Kieri,Piotr Nowak,J Peter Svensson

PloS one 20:e0320512 PubMed40267069

2025

Human cytomegalovirus infection induces L1 expression through UL38-dependent mTOR-KAP1 pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Sehong Park,Jiseok Jeong,Kwangseog Ahn

The Journal of biological chemistry 300:107788 PubMed39303914

2024

A novel EZH1/2 dual inhibitor inhibits GCB DLBCL through cell cycle regulation and M2 tumor-associated macrophage polarization.

Applications

Unspecified application

Species

Unspecified reactive species

Ran An,Zhimeng Zhang,Dongli Zhang,Yuqing Li,Yueling Lin,Hongtao Sun,Fang Xu,Manmei Li,Zhong Liu

Nature cardiovascular research 3:441-459 PubMed38765203

2024

Histone H1.0 couples cellular mechanical behaviors to chromatin structure.

Applications

Unspecified application

Species

Unspecified reactive species

Shuaishuai Hu,Douglas J Chapski,Natalie D Gehred,Todd H Kimball,Tatiana Gromova,Angelina Flores,Amy C Rowat,Junjie Chen,René R Sevag Packard,Emily Olszewski,Jennifer Davis,Christoph D Rau,Timothy A McKinsey,Manuel Rosa-Garrido,Thomas M Vondriska

Nature communications 14:2855 PubMed37202403

2023

Autophagy receptor NDP52 alters DNA conformation to modulate RNA polymerase II transcription.

Applications

Unspecified application

Species

Unspecified reactive species

Ália Dos Santos,Daniel E Rollins,Yukti Hari-Gupta,Hannah McArthur,Mingxue Du,Sabrina Yong Zi Ru,Kseniia Pidlisna,Ane Stranger,Faeeza Lorgat,Danielle Lambert,Ian Brown,Kevin Howland,Jesse Aaron,Lin Wang,Peter J I Ellis,Teng-Leong Chew,Marisa Martin-Fernandez,Alice L B Pyne,Christopher P Toseland

Nature communications 14:439 PubMed36707514

2023

Epigenetic regulation of Neuregulin 1 promotes breast cancer progression associated to hyperglycemia.

Applications

Unspecified application

Species

Unspecified reactive species

Changhu Lee,Min Kim,Chanho Park,Woobeen Jo,Jeong Kon Seo,Sahee Kim,Jiyoung Oh,Chu-Sook Kim,Han Suk Ryu,Kyung-Hun Lee,Jiyoung Park

BMC research notes 15:245 PubMed35799274

2022

Effects of end-stage osteoarthritis on markers of skeletal muscle Long INterspersed Element-1 activity.

Applications

Unspecified application

Species

Unspecified reactive species

Shelby C Osburn,Matthew A Romero,Paul A Roberson,Petey W Mumford,Derek A Wiggins,Jeremy S McAdam,Devin J Drummer,S Louis Bridges,Marcas M Bamman,Michael D Roberts

Nature communications 13:3145 PubMed35672415

2022

Dynamic nucleosome landscape elicits a noncanonical GATA2 pioneer model.

Applications

Unspecified application

Species

Unspecified reactive species

Tianbao Li,Qi Liu,Zhong Chen,Kun Fang,Furong Huang,Xueqi Fu,Qianben Wang,Victor X Jin

Nature communications 13:1346 PubMed35292632

2022

Myosin VI regulates the spatial organisation of mammalian transcription initiation.

Applications

Unspecified application

Species

Unspecified reactive species

Yukti Hari-Gupta,Natalia Fili,Ália Dos Santos,Alexander W Cook,Rosemarie E Gough,Hannah C W Reed,Lin Wang,Jesse Aaron,Tomas Venit,Eric Wait,Andreas Grosse-Berkenbusch,J Christof M Gebhardt,Piergiorgio Percipalle,Teng-Leong Chew,Marisa Martin-Fernandez,Christopher P Toseland

PLoS pathogens 16:e1008264 PubMed31999790

2020

Chromatin maturation of the HIV-1 provirus in primary resting CD4+ T cells.

Applications

Unspecified application

Species

Unspecified reactive species

Birgitta Lindqvist,Sara Svensson Akusjärvi,Anders Sönnerborg,Marios Dimitriou,J Peter Svensson
View all publications
websiteProtocolBooklet
en

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com